ArticleHeliyon2020
Increased serum IL-31 levels in chronic spontaneous urticaria and psoriasis with pruritic symptoms.
Article in Heliyon, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- IL-31: State of the Art for an Inflammation-Oriented Interleukin.International journal of molecular sciences · 2022Pooled it
- Calcipotriol-betamethasone foam modulates serum and tissue IL-17A, IL-31, IL-31RA, and substance P in mild-to-moderate psoriatic itch: A clinical and immunopathological study.JID innovations : skin science from molecules to population health · 2026Article
- Sex- and Gender-Related Differences in Pruritus in Dermatological Diseases: Insights into Inflammatory, Autoimmune, and Connective Tissue Disorders.Life (Basel, Switzerland) · 2026Review
- From neuroimmune circuits to targeted therapy of chronic pruritus.Pharmacological reviews · 2026Review
- The neuro-immune insights of itch: peripheral mechanisms and central glial contributions.Cellular & molecular biology letters · 2026Review
- Nemolizumab-induced psoriasiform dermatitis.JAAD case reports · 2025Article
- Increased serum interleukin-31 levels correlate with pruritus in psoriatic patients: a cross-sectional study in Vietnam.Dermatology reports · 2025Article
- Biological mechanisms and therapeutic prospects of interleukin-33 in pathogenesis and treatment of allergic disease.Journal of inflammation (London, England) · 2025Review
- Understanding the Intricate Pathophysiology of Psoriasis and Related Skin Disorders.International journal of molecular sciences · 2025Review
- Successful Treatment of Upadacitinib in Prurigo Nodularis: A Case Report and Review of the Literature.International medical case reports journal · 2025Article
- The roles of serum Th1, Th2, and Th17 cytokines in patients with chronic urticaria: a systematic review and meta-analysis.Frontiers in allergy · 2025Review
- Levels of serum inflammatory cytokines and their correlations with disease severity in patients with chronic spontaneous urticaria.Postepy dermatologii i alergologii · 2024Article
- Atopy in chronic urticaria: an important yet overlooked issue.Frontiers in immunology · 2024Review
- IL-31-Pruritus Interleukin: Serum Values and Clinical Impact in Chronic Spontaneous Urticaria-A Romanian Retrospective Study.Journal of clinical medicine · 2023Article
- In chronic spontaneous urticaria, IgE and C-reactive protein are linked to distinct microRNAs and interleukin-31.Clinical and translational allergy · 2023Article
- Crisaborole efficacy in murine models of skin inflammation and Staphylococcus aureus infection.Experimental dermatology · 2023Article
- Elevation of IgE in patients with psoriasis: Is it a paradoxical phenomenon?Frontiers in medicine · 2022Review
- Increased IL-31 expression in serum and tissue protein in prurigo nodularis.Therapeutic advances in chronic disease · 2022Article
- The Role of Crosstalk of Immune Cells in Pathogenesis of Chronic Spontaneous Urticaria.Frontiers in immunology · 2022Review
- Interleukin-31 and Pruritic Skin.Journal of clinical medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic spontaneous urticaria (CSU) is a common pruritic skin condition, the pathogenesis of which remains unclear. Interleukin-31 (IL-31) is a major pruritogenic cytokine that plays a role in inducing pruritus in various skin diseases.
aimTo 1) compare serum IL-31 levels among CSU patients, psoriasis patients with pruritic symptoms, and healthy subjects, 2) examine the correlations between serum IL-31 levels and disease severity, and 3) compare IL-31 levels in patients with and without CSU-associated auto-antibodies.
methodsPatients with CSU, psoriasis with pruritic symptoms, and healthy volunteers were recruited in the study. Serum IL-31 levels were measured with commercial kits. Baseline characteristics, urticaria activity score, psoriasis area severity index, pruritic intensity score, and related laboratory results were collected.
resultsSixty-five CSU patients, 30 psoriasis patients who had pruritus, and 31 healthy subjects participated in our study. The CSU patients had significantly higher mean serum IL-31 levels than the psoriasis patients (252.4 ± 115.5 vs 121.4 ± 16.6 pg/mL,
conclusionHigher serum IL-31 levels were found in patients with CSU and psoriasis with pruritic symptoms. This suggests that IL-31 has a possible role in the pathogenesis of CSU and psoriasis with pruritic symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.